Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study.

Clinical and translational science - 1 Apr 2022

Meloche Maxime, Leclair Grégoire, Jutras Martin, Oussaïd Essaïd, Gaulin Marie-Josée, Mongrain Ian, Busseuil David, Tardif Jean-Claude, Dubé Marie-Pierre, de Denus Simon

Abstract excerpt

Large, observational genetic studies are commonly used to identify genetic factors associated with diseases and disease-related traits. Such cohorts have not been commonly used to identify genetic predictors of drug dosing or concentrations, perhaps because of the heterogeneity in drug dosing and formulation, and the random timing of blood sampling. We hypothesized that large sample sizes relative to traditional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Sectional Studies
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Metoprolol

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 35122397
DOI: 10.1111/cts.13230
PMCID: PMC9010273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study.PMID 35122397Read ↗

Clinical Pharmacology and Pharmacogenetics in a Genomics Era: The DMET PlatformSemantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample.Semantic proximity Read ↗

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug-Gene Interactions for Commonly Used Drugs.Semantic proximity Read ↗

Empirical Drug Dosage Validates Pharmacogenomic Associations in All of Us.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

CYP450 genotype and pharmacogenetic association studies: a critical appraisal.Semantic proximity Read ↗

Investigating the genetic factors of medication dosing using biobank-linked drug purchase dataSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.